Ask AI

Owning Obesity in Psoriasis Care: A Multisite Quality Improvement Initiative to Improve Obesity Care for Patients With Psoriasis in Dermatology Settings

Video
This activity is available for 1.00 CME/CE credit(s).

Released: September 16, 2026

Expiration: September 15, 2027

See Activity Collection

Obesity and psoriasis share a complex, bidirectional relationship that has implications in dermatology practice, including the chronic inflammatory state of obesity and how that impacts psoriasis treatment strategies. Learn how to provide evidence-based care when screening patients and individualizing treatment planning, while engaging in compassionate, patient-centered conversations about weight and metabolic health.

Owning obesity in psoriasis VM

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with obesity and psoriasis (PsO) do you provide care for in a typical week?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 48-yr-old patient with moderate plaque PsO has a BMI of 35 kg/m². Despite topical treatment, the patient continues to have active skin disease.  

Which of the following best describes the relationship between PsO, obesity, and systemic inflammation?

4.

A 58-yr-old patient with mild-to-moderate PsO presents for routine follow-up. The patient has well-controlled hypertension and is not receiving biologic therapy.  

Based on the AAD-NPF guidelines, which of the following best describes the recommendation for obesity screening in this patient?

5.

Michael is a 45-yr-old man with moderate plaque PsO and obesity (BMI 36 kg/m²). He has persistent plaques involving the scalp, trunk, and extensor surfaces despite topical therapy and has a history of dyslipidemia. 

During follow-up, Michael is uncertain why his dermatologist is discussing his weight when his primary concern is PsO. Which approach would you use to address Michael’s concerns?